Emphysematous Cystitis in an Immunocompetent Patient on an SGLT2 Inhibitor
Abstract
Emphysematous cystitis is a rare, severe infection of the urinary bladder caused by gas-forming organisms like Escherichia coli and Klebsiella pneumoniae (K. pneumoniae). Common risk factors are female sex, chronic urinary infection, immunosuppression, diabetes mellitus, and neurogenic bladder. We report a case of K. pneumoniae emphysematous cystitis in a diabetic male patient being treated with empagliflozin. With this case report, we aim to highlight the potential role of an SGLT-2 inhibitor such as empagliflozin in developing severe urinary infections such as emphysematous cystitis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.